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Abstract
Background: Pneumococcal pneumonia is the most frequent form of pneumonia. We herein assessed the
effectiveness of the 23-valent pneumococcal polysaccharide vaccine (PPSV23) in the prevention of pneumonia
overall in rheumatoid arthritis (RA) patients at risk for infections. We hypothesized that PPSV23 vaccination is
superior in preventing pneumococcal pneumonia compared with placebo in RA patients.
Methods: A prospective, multicenter, double-blinded, randomized, placebo-controlled (1:1) trial was conducted
across departments of rheumatology in Japanese National Hospital Organization hospitals. RA patients (n = 900)
who had been treated with biological or immunosuppressive agents were randomly assigned PPSV23 or placebo
(sodium chloride). The primary endpoints were the incidences of all-cause pneumonia and pneumococcal pneumonia.
The secondary endpoint was death from pneumococcal pneumonia, all-cause pneumonia, or other causes. Cox
regression models were used to estimate the risk of pneumonia overall for the placebo group compared with
the vaccine group.
Results: Seventeen (3.7%) of 464 patients in the vaccine group and 15 (3.4%) of 436 patients in the placebo
group developed pneumonia. There was no difference in the rates of pneumonia between the two study groups.
The overall rate of pneumonia was 21.8 per 1000 person-years for patients with RA. The presence of interstitial
pneumonia (hazard ratio: 3.601, 95% confidence interval: 1.547–8.380) was associated with an increased risk of
pneumonia in RA patients.
Conclusion: PPSV23 does not prevent against pneumonia overall in RA patients at relative risk for infections. Our
results also confirm that the presence of interstitial lung disease is associated with pneumonia in Japanese patients
with RA.
Trial registration: UMIN-CTR UMIN000009566. Registered 17 December 2012.
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Background
Patients with rheumatoid arthritis (RA) are at increased
risk of serious infections. Although a newer class of bio-
logic disease-modifying antirheumatic drugs (bDMARDs)
has significantly advanced the treatment of RA, these
drugs are associated with an increased risk of several types
of infections [1, 2]. Pneumonia is also one of the major
causes of mortality in patients with RA [3]. Influenza and
pneumococcal infections are two vaccine-preventable
infectious diseases that have been associated with high
morbidity in patients with RA caused by immunosuppres-
sive treatments [4, 5]. In view of these data highlighting
the increased risk of infectious diseases in RA patients re-
ceiving immunosuppressive treatments and the awareness
and performance of vaccinations, clear recommendations
for vaccinations under the use of biological agents is
needed.
Streptococcus pneumoniae is the most common cause
of community-acquired pneumonia [6]. Recent randomized
controlled trials (RCTs) demonstrated that the 23-valent
pneumococcal polysaccharide vaccine (PPSV23) is effective
in the prevention of invasive pneumococcal disease
among high-risk older populations [7]. However, the
vaccine’s protective efficacy against pneumococcal
pneumonia in immunosuppressed people including pa-
tients with autoimmune diseases remains unknown [8].
PPSV23 was licensed more than 30 years ago and is
recommended as the standard intervention for the
older population (>60 years of age) and adults with
underlying diseases [9]. PPSV23 is also strongly recom-
mended for patients with autoimmune inflammatory
rheumatic diseases [10]. However, data regarding effi-
cacy of pneumococcal vaccines in patients with RA re-
ceiving immunotherapy including biological agents are
rare and often conflicting. We therefore conducted a
prospective, multicenter, double-blinded, randomized,
placebo-controlled trial to determine the efficacy of
PPSV23 in patients with RA receiving immunosuppres-
sive treatments. Our primary objective was to assess
the effectiveness of PPSV23 in the prevention of
pneumococcal pneumonia and pneumonia overall in
RA patients at risk of pneumonia.
Methods
Study design and patient population
We performed a double-blinded, randomized, placebo-
controlled trial. Patients with clinically diagnosed RA
were recruited in National Hospital Organization (NHO)
hospitals throughout Japan (the trial was conducted in
NHO 32 hospitals) from September 2010 to December
2012 [11]. The risk of infections was reported to be associ-
ated with their comorbidity and treatments in RA patients
[12]. Eligible patients were therefore divided into the
following groups: patients with rheumatoid lung disease
(n = 144), patients treated with biological agents (n = 510;
TNF inhibitors = 336, toclizumab = 124, abatacept = 50),
patients treated with immunosuppressive agents (n = 144),
patients receiving more than 5 mg/day of prednisone
(n = 241), and patients classified as Steinbrocker stage 3
or 4 (n = 485). Almost all patients (>93%) initiated bio-
logics >3 months prior to study entry. Patients were
excluded if they had previously received pneumococcal
vaccination. Eligible RA patients were assigned ran-
domly to the vaccine group or the placebo group. A
statistician who was not on the study team performed
the randomization using a random number table and
numbered the containers accordingly.
The following parameters were analyzed when the pa-
tient was first admitted to the study: swollen joint count,
tender joint count, patient global assessment of disease
activity, physician global assessment of disease activity,
Health Assessment Questionnaire Disability Index score,
serum levels of C-reactive protein (CRP), and Disease
Activity Score 28-joint assessment with CRP [13]. This
study was registered in UMIN-CTR (www.umin.ac.jp/
ctr/UMIN-CTR; UMIN000009566).
Intervention
Investigators in each NHO hospital registered patient in-
formation to the NHO’s central data center through an
online system. According to the predetermined alloca-
tion code book, either vaccine or placebo (1:1) was sim-
ply allocated in the order of registration. Patients were
randomly assigned to receive either 0.5 ml (25 μg) of
PPSV23 (Pneumovax NP; Merck Sharp & Dohme Corp.,
Tokyo, Japan) or 0.5 ml of placebo (sodium chloride)
subcutaneously in the upper arm. The placebo medica-
tion was identical in color. The vaccines were prepared
in a masked fashion for those who administered it,
blinding both the administrator of the vaccine and the
patient to the type of vaccine given. Vaccine and placebo
were presented in identical, single-dose syringes and
needle combinations that were labeled with sequential
study numbers only. A statistician who was not on the
study team performed the randomization using a random
number table and numbered the containers accordingly.
Patients were instructed to record local reactions (e.g.,
redness, swelling, and tenderness) and systemic reactions
(e.g., fever, nausea, and vomiting). Patients were also
monitored for 12 months after enrollment to follow the
development of pneumonia, including that stemming
from pneumococcal disease.
Outcome measures and definitions
The primary effectiveness endpoint was the prevention
of overall pneumonia using an intention-to-treat (ITT)
approach. The primary endpoints were pneumonia and
pneumococcal pneumonia. Pneumonia was diagnosed by
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the medical staff of the respiratory unit at the affiliated
hospital according to the presence of clinical symptoms
and a new infiltrate on chest radiography. Pneumococcal
pneumonia was diagnosed from a positive blood, pleural
fluid, or sputum culture or from a positive pneumococ-
cal antigen test result using a urine sample. Information
on fatal cases was obtained from a provincial registry,
which is based on death certificates written by the at-
tending physicians. During the study period, the patient
was instructed to contact the local doctor responsible
for the study if he or she developed a fever of 38 °C or
greater for more than 3 days, with or without respiratory
tract symptoms, or if he or she had any other cause to
suspect recurrent pneumonia. Chest radiography was
performed upon clinical suspicion of pneumonia. If
pneumonia was confirmed, blood, sputum, and urine
samples were obtained from the patient, if possible, for
etiological diagnosis. Blood testing was performed using
routine procedures and quantitative sputum cultures
were tested using purulent samples. The secondary
effectiveness endpoint was all cases of death.
Statistical analyses
Data are expressed as the mean (standard deviation) and
analyzed using the SPSS software program. For univariate
analyses, the χ2 test or Fisher’s exact test was used for
categorical data and the Mann–Whitney U test for con-
tinuous variables. The primary or secondary effectiveness
endpoint was evaluated by χ2 test or Fisher’s exact test.
Logistic regression analysis was used to estimate the ef-
fectiveness of PPSV23 in preventing pneumococcal
pneumonia, nonpneumococcal pneumonia, and all-cause
pneumonia. Kaplan–Meier methods were used to cal-
culate the survival curves. The log-rank test was used
for time to event analyses and Cox regression models
were used to calculate hazard ratios. P values are two-
tailed, with P < 0.05 considered statistically significant.
All data processing and analyses were performed using
the Statistical Analysis System (SAS) and SPSS version
18 software (SPSS, Chicago, IL, USA). According to the
sample size calculation, 1600 evaluable patients were
required (800 in each group). We assumed that the risk
of pneumonia among RA patients was 2 cases per 100
patient-years and vaccine efficacy was 50% according to
previous clinical studies and epidemiology data available
in Japan (references). Also, a type I error probability of
0.05 (two-sided) and a statistical power of 80% were
selected.
Results
Consecutive eligible patients between December 2012
and March 2014 were reviewed for inclusion. Of 989 pa-
tients, 59 patients were excluded (Fig. 1). The reasons
for exclusion included inability to obtain the informed
consent (n = 41) and conflict with the exclusion criteria
(n = 18), including previous PPSV23 vaccination (n = 2).
Among the remaining 930 patients, 18 patients withdrew
consent after randomization. Thus, 912 patients were
ultimately included; 472 were randomly assigned vaccine
and 440 placebo.
The trial was conducted in accordance with the ori-
ginal protocol and there was no change in the outcome
Fig. 1 Flow diagram of patient enrollment. IRB institutional review board, ITT intention-to-treat, PPSV23 23-valent pneumococcal polysaccharide vaccine
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measures. In November 2014, however, the Committee
on Immunization Practices of the Ministry of Health,
Labour and Welfare in Japan stated that all adults
≥65 years of age should receive PPSV23 and began pro-
moting routine vaccination with PPSV23. In response to
this public comment, the NHO central IRB recom-
mended stopping this trial continuation and vaccination
with PPSV23 for all subjects receiving placebo after
being keyed “open”. We decided trial discontinuation be-
fore the interim analysis according to this recommenda-
tion. Participants aged ≥65 years receiving placebo were
thus assigned to receive PPSV23 vaccination and forced
into discontinuation of follow-up until December 31, 2014.
In this study, participants in the forced discontinuation
groups were keyed “open” and received PPSV23 even
when they were assigned to receive placebo (Fig. 1). The
primary endpoint was assessed in the ITT population,
which included all randomized patients regardless of the
forced discontinuation. Of 912 patients who were ran-
domized to PPSV23 (n = 483) or placebo (n = 447), 12
patients lost to follow-up were excluded from the ITT
analysis. The ITT population therefore included 900
patients (Fig. 1).
Demographic data for the two groups are presented in
Table 1. The exposure time was 765.7 person-years
(mean 1.7 years) in the vaccine group and 703.7 (mean
1.6 years) person-years in the placebo group. Patient
characteristics were similar in both groups. During the
follow-up period, pneumonia was diagnosed in 32 (3.6%)
of the 900 patients; pneumonia was diagnosed in 15
(3.4%) of the 436 patients in the placebo group and in
17 (3.7%) of the 464 patients in the vaccine group. The
incidence of pneumonia per 1000 person-years was 21.3
and 22.2 in the placebo and vaccine groups, respectively.
The incidence rate for pneumonia in the vaccine group
did not differ from that in the placebo group (P = 0.856).
Sputum cultures and blood cultures were obtained in
18 and 14 episodes of pneumonia and urine samples for
pneumococcal antigen detection were obtained in 21
episodes of pneumonia. An etiological diagnosis was ob-
tained in 10 (15.6%) of the 64 episodes of pneumonia.
Table 1 Baseline characteristics of 900 rheumatoid arthritis
patients at randomization to PPSV23 or placebo
Vaccine group Placebo group
(n = 464) (n = 436) P value
Demographics
Age (years) 63.3 ± 12.1 62.7 ± 11.8 0.529





Smoking history 90 (19.4%) 116 (26.6%) 0.010
Laboratory data
CRP (mg/dl) 0.49 ± 1.11 0.51 ± 0.99 0.298
Serum albumin (g/dl) 4.06 ± 0.38 4.06 ± 0.37 0.926
Serum creatinine
(mg/dl)




12.1 ± 10.4 11.6 ± 9.7 0.747
HAQ 0.66 ± 0.74 0.67 ± 0.75 0.918
DAS28 (CRP) 2.43 ± 1.10 2.51 ± 1.15 0.324
SDAI 8.00 ± 7.72 8.73 ± 8.55 0.252
CDAI 7.50 ± 7.38 8.24 ± 8.33 0.257
Comorbidity
Cardiovascular disease 127 (27.4%) 131 (30.0%) 0.375
CVA 14 (3.0%) 10 (2.3%) 0.501
Ischemic heart disease 9 (1.9%) 9 (2.1%) 0.894
Hypertension 109 (23.5%) 116 (26.6%) 0.281
Arrythmia 6 (1.3%) 5 (1.1%) 0.842
Cardiac failure 6 (1.3%) 4 (0.9%) 0.415
Metabolic disease 111 (23.9%) 96 (22.0%) 0.498
Hyperlipidemia 72 (15.5%) 56 (12.8%) 0.251
Hyperuricemia 0 9 (2.1%) 0.001
Diabetes 48 (10.3%) 45 (10.3%) 0.991
CKD 17 (3.7%) 18 (4.1%) 0.719
Autoimmune disease 23 (5.0%) 14 (3.2%) 0.187
Rheumatoid lung 81 (17.5%) 71 (16.3%) 0.890
Interstitial pneumonia 56 (12.1%) 46 (10.6%) 0.473
Bronchial lesion 19 (4.1%) 19 (4.4%) 0.845
Pleural lesion 6 (1.3%) 6 (1.4%) 0.914
COPD 11 (2.4%) 16 (3.7%) 0.254
NTM 7 (1.5%) 8 (1.8%) 0.702
Treatment
PSL 242 (52.2%) 214 (49.1%) 0.357
Dose of PSL (mg/day) 4.54 ± 2.79 4.71 ± 2.84 0.530
PSL ≥ 5 mg/day 130 (28.0%) 117 (26.8%) 0.691
MTX 300 (64.7%) 304 (69.7%) 0.106
Dose of MTX (mg/week) 8.01 ± 2.75 8.33 ± 2.85 0.227
MTX alone 40 (8.6%) 47 (10.8%) 0.273
Table 1 Baseline characteristics of 900 rheumatoid arthritis
patients at randomization to PPSV23 or placebo (Continued)
MTX + PSL 54 (11.6%) 49 (11.2%) 0.851
MTX + biologics 103 (22.2%) 107 (24.5%) 0.406
TAC 60 (12.9%) 60 (13.8%) 0.714
Biologics 257 (55.4%) 253 (58.0%) 0.425
Data presented as number (percentage) or mean ± standard deviation
PPSV23 23-valent pneumococcal polysaccharide vaccine, CRP C-reactive protein,
RA rheumatoid arthritis, HAQ Health Assessment Questionnaire Disability Index
score, DAS28 Disease Activity Score 28, SDAI simplified disease activity index, CDAI
clinical disease activity index, CVA cerebrovascular accident, CKD chronic kidney
disease, COPD chronic obstructive pulmonary disease, NTM nontuberculous
mycobacteria, PSL prednisolone, MTX methotrexate, TAC tacrolimus
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Causative pathogens were identified in 12 (37.5%) of the
32 participants. Pneumococcal pneumonia was diagnosed
in two participants in the vaccine group (2/17, 11.8%) and
one participant in the placebo group (1/15, 6.7%). The
causative agents of nonpneumococcal pneumonia were
Staphylococcus aureus (n = 2), Pseudomonas aeruginosa
(n = 2), Klebsiella pneumoniae (n = 1), Haemophilus
influenzae (n = 1), Escherichia coli (n = 1), Moraxella
catarrhalis (n = 1), and Neisseria sp. (n = 1). The inci-
dence rate of pneumococcal pneumonia was not signifi-
cantly different between the vaccine and placebo
groups (Table 2). One adverse event (bronchial asthma)
in the placebo group and three adverse events (intersti-
tial pneumonia, mycoplasma pneumonia, heart failure)
in the vaccine group were documented during the
follow-up period.
Kaplan–Meier survival curves were plotted for the
pneumonia-free survival between the vaccine and pla-
cebo groups (Fig. 2). The pneumonia free-survival rates
were not significantly different between the vaccine and
placebo groups.
For stratified analyses based on risk for developing
respiratory infections, patients were divided into the
following groups: patients with rheumatoid lung disease,
patients receiving biologics, patients receiving immuno-
suppressants (tacrolimus, mizoribine, and cyclosporine
A), patients receiving more than 5 mg/day of prednis-
one, and patients classified as Steinbrocker stage 3 or 4.
However, there was no significant difference in the num-
ber of pneumonia cases between the vaccine and placebo
groups in each subgroup (Table 3). Also, as we planned,
stratified analyses based on risk for developing respiratory
infections were conducted according to the following
groups: patients with rheumatoid lung disease, patients
with RA treated with biological agents, patients with RA
treated with immunosuppressive agents, patients receiving
more than 5 mg/day of prednisone, and patients classified
as Steinbrocker stage 3 or 4. However, there was no
significant difference in the number of pneumonia cases
between the vaccine and placebo groups in each subgroup
(Table 3). Age categories were not considered because
most of the study population were 65 years or older be-
cause of eligibility for pneumococcal vaccines in Japan.
Finally, we compared baseline data between patients
with or without pneumonia in the total subjects. A few
of the demographic and clinical variables were associated
with risk of pneumonia, as shown in Table 4. Older age
and the presence of interstitial pneumonia were found
to be predictive factors for pneumonia. The effect of
treatment variables on the risk of pneumonia was ana-
lyzed using univariate analyses (Table 5); however, no
treatment variable was identified as a risk factor for
pneumonia. A multivariate analysis of all variables is
presented in Table 6. The presence of interstitial pneu-
monia remained a significant risk factor for pneumonia
in RA patients. Kaplan–Meier curves stratified by the
Table 2 Incidence of primary endpoints in rheumatoid arthritis patients assigned to PPSV23 or placebo
Vaccine group (n = 464) Placebo group (n = 436)
Incidence rate per 1000
patient-years (n)
95% CI Incidence rate per 1000
patient-years (n)
95% CI P value
Pneumococcal pneumonia 2.6 (2) 0.7–9.5 1.4 (1) 0.3–8.0 0.523
Nonpneumococcal pneumonia 19.6 (15) 11.9–32.3 19.9 (14) 11.9–33.4 0.985
All-cause pneumonia 22.2 (17) 13.9–35.6 21.3 (15) 12.9–35.2 0.856
PPSV23 23-valent pneumococcal polysaccharide vaccine, CI confidence interval
Fig. 2 Pneumonia-free survival curves of RA patients receiving
PPSV23 and placebo. Statistically significant difference was not
observed between patients receiving PPSV23 and placebo (P = 0.084,
log-rank test)
Table 3 Primary endpoint (pneumonia) in each subgroup
Subgroup PPSV23 Placebo P value
With rheumatoid lung 12.3% (10/81) 5.6% (4/71) 0.1534
Receiving biologics 3.1% (8/257) 2.4% (6/253) 0.6085
Receiving immunosuppressants 4.1% (3/74) 2.9% (2/70) 0.6950
Receiving steroid
(>5 mg/day of prednisolone)
3.9% (5/130) 2.6% (3/117) 0.5698
With advanced stage 3.7% (9/246) 3.8% (9/239) 0.9502
Data presented as percentage (number)
PPSV23 23-valent pneumococcal polysaccharide vaccine
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presence of interstitial pneumonia showed a significant
difference between RA patients with or without intersti-
tial pneumonia. Additionally, the presence of interstitial
pneumonia significantly affected the pneumonia-free
survival rates of RA patients (Fig. 3).
Discussion
The effectiveness of PPSV23 in preventing pneumo-
coccal pneumonia remains controversial, especially in
high-risk individuals [14]. Although several studies
have demonstrated the effectiveness of PPSV23 [15],
few studies have focused on patients with autoimmune
diseases. To our knowledge, this is the first RCT to
evaluate this concern in patients with RA. We demon-
strated previously that PPSV23 vaccination induced
the serotype-specific IgG and functional opsonization
index responses were not impaired even in RA pa-
tients receiving immunosuppressive treatments [11].
However, we were unable to show that PPSV23 was ef-
fective in the prevention of pneumonia overall or
pneumococcal pneumonia. This might be because of
lack of power and shortened follow-up periods. The
fundamental difficulty in obtaining a definitive patho-
logical cause of pneumonia may also be related to
these negative data. Definitive pneumococcal pneumo-
nia (positive blood or sputum culture) is the most specific
outcome to evaluate vaccine effectiveness; however, it has
a low sensitivity. Therefore, we used the BinaxNOW® S.
pneumoniae Antigen Card test for diagnosis [16]. How-
ever, 13 of 34 pneumonia cases did not receive this urinary
antigen test and only a fraction of pneumonia cases
caused by S. pneumoniae were included in our analysis. A
Cochrane review also failed to show any protective
efficacy of PPSV23 in patients with chronic pulmonary
diseases [17]. Further high-quality trials with sufficient
sample size would be useful to confirm our findings.
Pneumococcal conjugate vaccines offer an alternative
approach to prevent pneumococcal disease. The seven-
valent pneumococcal conjugate has been shown to pro-
tect HIV-infected adults from recurrent pneumococcal
infection [18]. The effectiveness of PPSV23 preventing
Table 4 Baseline clinical and demographic data between RA
patients with or without pneumonia
Pneumonia Without pneumonia
(n = 32) (n = 868) P value
Demographics
Age (years) 68.6 ± 10.8 62.8 ± 11.9 0.010





Smoking history 7 (21.9%) 199 (22.9%) 0.889
Laboratory data
CRP (mg/dl) 1.14 ± 2.29 0.48 ± 0.97 0.023
Serum albumin
(g/dl)
3.95 ± 0.44 4.07 ± 0.37 0.210
Serum creatinine
(mg/dl)
0.70 ± 0.21 0.68 ± 0.31 0.248
RA characteristics
RA duration (years) 12.3 ± 8.3 11.9 ± 10.1 0.378
HAQ 0.78 ± 0.81 0.66 ± 0.74 0.564
DAS28 (CRP) 2.32 ± 0.97 2.48 ± 1.13 0.548
SDAI 6.72 ± 6.11 8.41 ± 8.20 0.237
CDAI 5.64 ± 4.76 7.94 ± 7.94 0.123
Comorbidity
Cardiovascular disease 13 (40.6%) 245 (28.2%) 0.128
CVA 2 (6.3%) 22 (2.5%) 0.209
Ischemic heart
disease
1 (3.1%) 17 (2.0%) 0.482
Hypertension 10 (31.3%) 215 (24.8%) 0.406
Arrythmia 2 (6.3%) 9 (1.0%) 0.055
Cardiac failure 2 (6.3%) 8 (0.9%) 0.046
Metabolic disease 10 (31.3%) 197 (22.7%) 0.259
Hyperlipidemia 6 (18.8%) 122 (14.1%) 0.297
Hyperuricemia 0 9 (1.0%) 0.721
Diabetes 5 (15.6%) 88 (10.1%) 0.229
CKD 2 (6.3%) 33 (3.8%) 0.356
Autoimmune disease 1 (3.1%) 36 (4.1%) 0.617
Rheumatoid lung 14 (43.8%) 138 (15.9%) <0.0001
Interstitial pneumonia 11 (34.4%) 91 (10.5%) <0.0001
Bronchial lesion 3 (9.4%) 35 (4.0%) 0.148
Pleural lesion 1 (3.1%) 11 (1.3%) 0.354
COPD 0 27 (3.1%) 0.371
NTM 1 (3.1%) 14 (1.6%) 0.422
PPSV23 vaccination 17 (53.1%) 447 (51.5%) 0.856
Treatment
PSL 18 (56.3%) 438 (50.5%) 0.520
Dose of prednisolone
(mg/day)
5.61 ± 4.90 4.58 ± 2.69 0.521
Table 4 Baseline clinical and demographic data between RA
patients with or without pneumonia (Continued)
MTX 20 (62.5%) 584 (67.3%) 0.572
Dose of MTX (mg/week) 7.90 ± 2.38 8.18 ± 2.82 0.660
TAC 4 (12.5%) 116 (13.4%) 0.573
Biologics 14 (43.8%) 496 (57.1%) 0.133
Data presented as number (percentage) or mean ± standard deviation
PPSV23 23-valent pneumococcal polysaccharide vaccine, CRP C-reactive protein,
RA rheumatoid arthritis, HAQ Health Assessment Questionnaire Disability Index
score, DAS28 Disease Activity Score 28, SDAI simplified disease activity index,
CDAI clinical disease activity index, CVA cerebrovascular accident, CKD chronic
kidney disease, COPD chronic obstructive pulmonary disease, NTM nontuberculous
mycobacteria, PSL prednisolone, MTX methotrexate, TAC tacrolimus
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pneumococcal infections among patients with chronic
pulmonary diseases is unclear [19]. However, the efficacy
and cost-effectiveness of PPSV23 in preventing IPD among
the general population had been demonstrated [20]. Based
on the new guidelines, the sequential administration of
conjugate and polysaccharide pneumococcal vaccines has
recently been the most appropriate approach for the pre-
vention of pneumonia in the general population [21]. Our
study confirmed that polysaccharide vaccine alone is not
effective for prevention of pneumonia. Therefore, sequen-
tial administration of PCV13 and PPSV23 could also be an
appropriate approach for the prevention for pneumonia in
RA patients receiving immunosuppresssive treatments.
Pneumonia is the most common type of infection in
RA [22]. Previous studies demonstrated increased
frequencies of pneumonia with higher mortality in RA
patients [23]. Our data showed that the incidence of
pneumonia was 2.14 per 100 person-years in RA
patients with a relatively high risk for infections. Gluco-
corticoid use was also shown to increase the risk of
serious infections in a dose-dependent manner in RA
patients [24]. The magnitude of the risk of infection as-
sociated with prednisolone dose > 10 mg/day was similar
to that associated with TNF-α antagonists [25]. However,
neither glucocorticoid dosage nor bDMARD use was
demonstrated to be a predictor of pneumonia risk in our
study. Of note, we found no evidence for increased rates
of pneumonia associated with bDMARD use. However,
our data are inconsistent with a recent meta-analysis of
Table 5 Predictors of pneumonia in RA patients by the Cox-hazard
model (univariate analysis)
Hazard ratio P value 95% CI
Demographics
Age (years) 1.058 0.002 1.021–1.095
Gender, male 1.073 0.870 0.464–2.480
Laboratory data
CRP (mg/dl) 1.321 <0.0001 1.140–1.531
Serum albumin (g/dl) 0.414 0.051 0.171–1.004
Serum creatinine (mg/dl) 1.358 0.413 0.652–2.828
RA characteristics
RA duration (years) 1.002 0.927 0.968–1.036
HAQ 1.219 0.366 0.794–1.871
DAS28 (CRP) 0.894 0.498 0.646–1.237
SDAI 0.970 0.281 0.919–1.025
CDAI 0.949 0.115 0.890–1.013
Comorbidity
Smoking history 0.936 0.877 0.405–2.165
Cardiovascular disease 1.745 0.122 0.862–3.533
Metabolic disease 1.612 0.211 0.763–3.405
CKD 1.814 0.415 0.433–7.592
Autoimmune disease 0.723 0.750 0.099–5.299
Interstitial pneumonia 4.449 <0.0001 2.143–9.237
PPSV23 vaccination 1.048 0.894 0.523–2.099
Treatment
PSL 1.314 0.443 0.654–2.643
Dose of prednisolone (mg/day) 1.117 0.102 0.978–1.276
MTX 0.778 0.493 0.381–1.593
Dose of MTX (mg/week) 0.962 0.634 0.821–1.128
TAC 0.956 0.934 0.335–2.727
Biologics 0.544 0.088 0.270–1.094
PPSV23 23-valent pneumococcal polysaccharide vaccine, CRP C-reactive protein,
RA rheumatoid arthritis, HAQ Health Assessment Questionnaire Disability Index
score, DAS28 Disease Activity Score 28, SDAI simplified disease activity index,
CDAI clinical disease activity index, CKD chronic kidney disease, PSL prednisolone,
MTX methotrexate, TAC tacrolimus, CI confidence interval
Table 6 Predictors of pneumonia in RA patients by the Cox-hazard
model (Multivariate analysis)
Hazard ratio P value 95% CI
Demographics
Age (years) 1.039 0.068 0.997–1.083
Gender, male 0.580 0.317 0.200–1.686
Smoking history 1.247 0.670 0.452–3.443
Laboratory data
CRP (mg/dl) 1.384 0.268 0.779–2.459
Serum albumin (g/dl) 0.917 0.877 0.305–2.758
Serum creatinine (mg/dl) 1.550 0.366 0.599–4.005
RA characteristics
RA duration (years) 1.010 0.582 0.974–1.048
HAQ 1.202 0.506 0.699–2.067
DAS28 (CRP) 1.026 0.936 0.545–1.933
SDAI 0.945 0.845 0.534–1.670
CDAI 0.944 0.851 0.517–1.723
Comorbidity
Cardiovascular disease 1.138 0.749 0.515–2.518
Metabolic disease 1.283 0.542 0.576–2.856
CKD 1.402 0.689 0.268–7.344
Autoimmune disease 0.468 0.494 0.053–4.137
Interstitial pneumonia 3.611 0.003 1.553–8.399
PPSV23 vaccination 0.849 0.656 0.414–1.743
Treatment
PSL 1.081 0.846 0.492–2.375
MTX 1.431 0.390 0.632–3.240
TAC 0.712 0.552 0.232–2.182
Biologics 0.664 0.307 0.302–1.458
PPSV23 23-valent pneumococcal polysaccharide vaccine, CRP C-reactive protein,
RA rheumatoid arthritis, HAQ Health Assessment Questionnaire Disability Index
score, DAS28 Disease Activity Score 28, SDAI simplified disease activity index,
CDAI clinical disease activity index, CKD chronic kidney disease, PSL prednisolone,
MTX methotrexate, TAC tacrolimus, CI confidence interval
Izumi et al. Arthritis Research & Therapy  (2017) 19:15 Page 7 of 10
RCTs of RA patients who received bDMARDs [26]. Never-
theless, the included patients and analytical methods in
previous studies differed significantly from those in this
study. Additionally, the relatively lower corticosteroid dos-
age prescribed to our RA patients may have influenced the
association between glucocorticoid dosage and the occur-
rence of pneumonia.
As reported for RA patients, older age and pulmonary
disease were found to be independently associated with
bacterial infection. Among variables, preexisting inter-
stitial pneumonia and older age were demonstrated to
be associated with the risk of pneumonia [27]. Among
the extra-articular manifestations of RA, there has been
renewed interest in pulmonary complications directly
associated with RA, which manifest as a variety of clini-
cal signs such as pleural disease, pulmonary nodules,
interstitial lung disease (ILD), and airway disease [28].
A large observational cohort study in Japan showed
that the presence of ILD is one of the factors associated
with increased mortality in RA patients [29]. Our data
are consistent with these previous studies. Although
the pathophysiologic mechanism for this finding has
not been elucidated, decreased ciliary and respiratory
epithelial function seen in patients with interstitial
pneumonia may contribute to the higher frequency of
pneumonia [30].
There are several limitations associated with this
study. First, the forced discontinuation of follow-up is
unusual and the disconfirmation rates were high. Thus,
potential bias introduced by the discontinuation group
(≥65 years of age) should be considered. Second, our
sample size was limited. For sample size calculation, we
assumed, from previously published data on RA patients
under biologic treatment [31], a rate of pneumonia of
2.5/100 patient-years. Based on these assumptions, we
primarily calculated that we needed 714 patients receiving
PPSV23 and 714 patients receiving placebo to confirm
50% reduction of pneumonia occurrence during 2 years of
follow-up at an α error of 0.10 and a β error of 0.80. How-
ever, we could not reserve sufficient sample size, and the
possibility of an underpowered study cannot be denied.
Third, our RA population consisted of groups at high
risk for infections, and thus our results may not be
generalizable to other RA populations. Fourth, we can-
not rule out the imprecision of our complete data due
to unreliability in the diagnosis of pneumonia.
The strengths of our study include examination of an
RA patient cohort using data captured from the largest
NHO data center. Laboratory results and physician
notes are available in this data resource and allow for
examination of potential risk factors that are not typically
available when using only administrative claims data. Our
study represents the most comprehensive, hospital-based
study with the outcomes in all enrolled patients followed
completely. The participants in this study, in contrast to
those in many clinical trials, were similar demographically
to general RA patients. Our data can therefore provide a
great deal of useful information about generalizability.
Conclusions
Our data showed that PPSV23 vaccination was not effective
in preventing pneumonia. While PPSV23 vaccination is
recommended for adults ≥65 years of age, our results
suggested uncertainty regarding its effectiveness for
pneumonia in RA patients at high risk for infections.
Clinicians should keep in mind the patient’s age and
the presence of interstitial pneumonia because such pa-
tients are at an increased risk of developing pneumonia.
Abbreviations
ILD: Interstitial lung disease; NHO: Japanese National Hospital Organization;
PCV: Pneumococcal conjugate vaccine; PPV23: 23-Valent pneumococcal
polysaccharide vaccine; RA: Rheumatoid arthritis
Acknowledgements
This study could not have been accomplished without the effective and
dedicated participation of each of the following contributors: Takao Yamanaka,
MD (NHO Minami-Okayama Medical Center); Shiro Ohshima, MD (NHO Osaka
Minami Medical Center); Yojiro Kawabe, MD (NHO Ureshino Medical Center);
Akira Okamoto, MD (NHO Himeji Medical Center); Hisaji Ohshima, MD (NHO
Tokyo Medical Center); Naoya Mori, MD (NHO Shinshu Ueda Medical Center);
Akinori Matsumori, MD (NHO Kochi National Hospital); Tetsuo Ozawa, MD
(NHO Niigata National Hospital); Koichiro Takahi, MD (NHO Toneyama
National Hospital); Kiyoki Kitagawa, MD (NHO Kanazawa Medical Center);
Norikazu Hamada, MD (NHO Kure Medical Center); Shigeru Yoshizawa, MD
(NHO Fukuoka Hospital); Kyoichi Nakajima, MD (NHO East Saitama National
Hospital); Norio Tamura, MD (NHO Sendai Nishitaga National Hospital);
Itou Jun, MD (NHO Hachinohe National Hospital); Hideaki Nagai, MD
(NHO Tokyo National Hospital); Yasuhiro Komiya, MD (NHO Shigaraki
Hospital); Masaharu Kawabata, MD (NHO Minami Kyushu National hospital).
Fig. 3 Pneumonia-free survival curves of RA patients with or without
interstitial lung disease (ILD). Curves are stratified by the presence or
absence of ILD. Statistically significant differences were observed
between patients with or without ILD (P < 0.0001, log-rank test)
Izumi et al. Arthritis Research & Therapy  (2017) 19:15 Page 8 of 10
Funding
This study was supported by a grant from the Japanese National Hospital
Organization (NHO)-Evidence-based Medicine (EBM) study group.
Availability of data and materials
Not applicable.
Authors’ contributions
YI, YA, HF, KK, KO, and KM carried out the molecular genetic studies, participated
in the sequence alignment, and drafted the manuscript. YA and KM carried out
the immunoassays and revised the manuscript. YI, ST, FH, HI, RM, TM, SM, TF, NI,
HT, KS, TS, YS, YO, MK, and KI participated in the sequence alignment and
drafted the manuscript. MA, YJ, and HK participated in the design of the
study, performed the statistical analysis, and helped to revise the manuscript. YI,
MA, and KM conceived of the study, participated in its design and coordination,
and helped to draft the manuscript. All authors read and approved the final
manuscript.
Competing interests
The authors declare that they have no competing interests.
Consent for publication
Not applicable.
Ethics approval and consent to participate
This study was approved by the ethical committees of National Hospital
Organization central Institutional Review Board (No. 0512014, 2012). All patients
provided written informed consent.
Author details
1Japanese National Hospital Organization (NHO) (Evidence-based Medicine
Study Group), Higashigaoka 2-5-23, Meguro, Tokyo 152-8621, Japan.
2Department of Public Health and Epidemiology, Meiji Pharmaceutical
University, Noshio 2-522-1, Kiyose, Tokyo 204-8588, Japan. 3Research Institute
for Microbial Diseases, Osaka University, Yamadaoka 3-1, Suita, Osaka
565-8563, Japan. 4Infectious Diseases Surveillance Center, National Institute of
Infectious Diseases, Toyama 1-23-1, Shinjuku, Tokyo 162-8640, Japan.
5Department of Rheumatology, Fukushima Medical University, Hikarigaoka 1,
Fukushima 960-1295, Japan.
Received: 26 May 2016 Accepted: 9 December 2016
References
1. Doran MF, Crowson CS, Pond GR, O'Fallon WM, Gabriel SE. Frequency of
infection in patients with rheumatoid arthritis compared with controls: a
population-based study. Arthritis Rheum. 2002;46:2287–93.
2. Bongartz T, Sutton AJ, Sweeting MJ, Buchan I, Matteson EL, Montori V.
Anti-TNF antibody therapy in rheumatoid arthritis and the risk of serious
infections and malignancies: systematic review and meta-analysis of rare
harmful effects in randomized controlled trials. JAMA. 2006;295:2275–85.
3. Naz SM, Symmons DP. Mortality in established rheumatoid arthritis. Best
Pract Res Clin Rheumatol. 2007;21:871–83.
4. van Assen S, Elkayam O, Agmon-Levin N, Cervera R, Doran MF, Dougados M,
et al. Vaccination in adult patients with auto-immune inflammatory rheumatic
diseases: a systematic literature review for the European League Against
Rheumatism evidence-based recommendations for vaccination in adult
patients with auto-immune inflammatory rheumatic diseases. Autoimmun Rev.
2011;10:341–52.
5. van Assen S, Agmon-Levin N, Elkayam O, Cervera R, Doran MF, Dougados M, et
al. EULAR recommendations for vaccination in adult patients with autoimmune
inflammatory rheumatic diseases. Ann Rheum Dis. 2011;70:414–22.
6. Diao WQ, Shen N, Yu PX, Liu BB, He B. Efficacy of 23-valent pneumococcal
polysaccharide vaccine in preventing community-acquired pneumonia
among immunocompetent adults: a systematic review and meta-analysis of
randomized trials. Vaccine. 2016;34:1496–503.
7. Maruyama T, Taguchi O, Niederman MS, Morser J, Kobayashi H, Kobayashi T,
et al. Efficacy of 23-valent pneumococcal vaccine in preventing pneumonia
and improving survival in nursing home residents: double blind, randomised
and placebo controlled trial. BMJ. 2010;340:c1004.
8. Glück T, Müller-Ladner U. Vaccination in patients with chronic rheumatic or
autoimmune diseases. Clin Infect Dis. 2008;46:1459–65.
9. Moberley S, Holden J, Tatham DP, Andrews RM. Vaccines for preventing
pneumococcal infection in adults. Cochrane Database Syst Rev. 2013;1,
CD000422.
10. Perry LM, Winthrop KL, Curtis JR. Vaccinations for rheumatoid arthritis.
Curr Rheumatol Rep. 2014;16:431.
11. Migita K, Akeda Y, Akazawa M, Tohma S, Hirano F, Ideguchi H, et al.
Pneumococcal polysaccharide vaccination in rheumatoid arthritis patients
receiving tacrolimus. Arthritis Res Ther. 2015;17:149.
12. Listing J, Gerhold K, Zink A. The risk of infections associated with
rheumatoid arthritis, with its comorbidity and treatment. Rheumatology.
2013;52:53.
13. Matsui T, Kuga Y, Kaneko A, Nishino J, Eto Y, Chiba N, et al. Disease Activity
Score 28 (DAS28) using C-reactive protein underestimates disease activity
and overestimates EULAR response criteria compared with DAS28 using
erythrocyte sedimentation rate in a large observational cohort of
rheumatoid arthritis patients in Japan. Ann Rheum Dis. 2007;66:1221–6.
14. Wiemken TL, Carrico RM, Klein SL, Jonsson CB, Peyrani P, Kelley RR, et al.
The effectiveness of the polysaccharide pneumococcal vaccine for the
prevention of hospitalizations due to Streptococcus pneumoniae
community-acquired pneumonia in the elderly differs between the sexes:
results from the Community-Acquired Pneumonia Organization (CAPO)
international cohort study. Vaccine. 2014;32:2198–203.
15. Ochoa-Gondar O, Vila-Corcoles A, Rodriguez-Blanco T, Gomez-Bertomeu F,
Figuerola-Massana E, Raga-Luria X, et al. Effectiveness of the 23-valent
pneumococcal polysaccharide vaccine against community-acquired
pneumonia in the general population aged ≥ 60 years: 3 years of follow-up
in the CAPAMIS study. Clin Infect Dis. 2014;58:909–17.
16. Sinclair A, Xie X, Teltscher M, Dendukuri N. Systematic review and meta-
analysis of a urine-based pneumococcal antigen test for diagnosis of
community-acquired pneumonia caused by Streptococcus pneumoniae.
J Clin Microbiol. 2013;51:2303–10.
17. Walters JA, Smith S, Poole P, Granger RH, Wood-Baker R. Injectable vaccines
for preventing pneumococcal infection in patients with chronic obstructive
pulmonary disease. Cochrane Database Syst Rev. 2010;(11):CD001390.
18. French N, Gordon SB, Mwalukomo T, White SA, Mwafulirwa G, Longwe H, et
al. A trial of a 7-valent pneumococcal conjugate vaccine in HIV-infected
adults. N Engl J Med. 2010;362:812–22.
19. Vila-Corcoles A, Ochoa-Gondar O, Rodriguez-Blanco T, Gutierrez-Perez A,
Vila-Rovira A. Clinical effectiveness of 23-valent pneumococcal
polysaccharide vaccine against pneumonia in patients with chronic
pulmonary diseases: a matched case-control study. Hum Vaccin
Immunother. 2012;8:639.
20. Moberley SA, Holden J, Tatham DP, Andrews RM. Vaccines for preventing
pneumococcal infection in adults. Cochrane Database Syst Rev. 2008;23,
CD000422.
21. Pilishvili T, Bennett NM. Pneumococcal disease prevention among adults:
strategies for the use of pneumococcal vaccines. Vaccine. 2015;33
Suppl 4:D60–5.
22. Doran MF, Crowson CS, Pond GR, O'Fallon WM, Gabriel SE. Predictors of
infection in rheumatoid arthritis. Arthritis Rheum. 2002;46:2294–300.
23. Nakajima A, Inoue E, Tanaka E, Singh G, Sato E, Hoshi D, et al. Mortality and
cause of death in Japanese patients with rheumatoid arthritis based on a
large observational cohort, IORRA. Scand J Rheumatol. 2010;39:360-7.
24. Dixon WG, Suissa S, Hudson M. The association between systemic glucocorticoid
therapy and the risk of infection in patients with rheumatoid arthritis: systematic
review and meta-analyses. Arthritis Res Ther. 2011;13:R139.
25. Listing J, Gerhold K, Zink A. The risk of infections associated with rheumatoid
arthritis, with its comorbidity and treatment. Rheumatology (Oxford).
2013;52:53–61.
26. Singh JA, Cameron C, Noorbaloochi S, Cullis T, Tucker M, Christensen R, et al.
Risk of serious infection in biological treatment of patients with rheumatoid
arthritis: a systematic review and meta-analysis. Lancet. 2015;386:258–65.
27. Crowson CS, Hoganson DD, Fitz-Gibbon PD, Matteson EL. Development and
validation of a risk score for serious infection in patients with rheumatoid
arthritis. Arthritis Rheum. 2012;64:2847–55.
28. Kelly CA, Saravanan V, Nisar M, Arthanari S, Woodhead FA, Price-Forbes AN,
et al. Rheumatoid arthritis-related interstitial lung disease: associations,
prognostic factors and physiological and radiological characteristics—a
large multicentre UK study. Rheumatology (Oxford). 2014;53:1676–82.
Izumi et al. Arthritis Research & Therapy  (2017) 19:15 Page 9 of 10
29. Solomon JJ, Ryu JH, Tazelaar HD, Myers JL, Tuder R, Cool CD, et al. Fibrosing
interstitial pneumonia predicts survival in patients with rheumatoid arthritis-
associated interstitial lung disease (RA-ILD). Respir Med. 2013;107:1247–52.
30. Lake F, Proudman S. Rheumatoid arthritis and lung disease: from mechanisms
to a practical approach. Semin Respir Crit Care Med. 2014;35:222–38.
31. Yun H, Xie F, Delzell E, Levitan EB, Chen L, Lewis JD, et al. Comparative risk
of hospitalized infection associated with biologic agents in rheumatoid
arthritis patients enrolled in Medicare. Arthritis Rheum. 2016;68:56–66.
•  We accept pre-submission inquiries 
•  Our selector tool helps you to find the most relevant journal
•  We provide round the clock customer support 
•  Convenient online submission
•  Thorough peer review
•  Inclusion in PubMed and all major indexing services 
•  Maximum visibility for your research
Submit your manuscript at
www.biomedcentral.com/submit
Submit your next manuscript to BioMed Central 
and we will help you at every step:
Izumi et al. Arthritis Research & Therapy  (2017) 19:15 Page 10 of 10
